文献速递腹部技术与安全US

整合超声造影特征与血清生物标志物的在线工具优化肝细胞癌无创诊断

Integrating Contrast-Enhanced Ultrasound Features and Serum Biomarkers in an Online Tool Optimizes Noninvasive Hepatocellular Carcinoma Diagnosis.
PubMed 文献 · Ultrasound Med Biol · 2025-11-29

回顾性纳入1487例接受肝脏超声造影患者,以病理或综合影像及临床随访为参考标准,通过logistic回归构建包含性别、年龄、AFP、DCP、动脉期高增强和晚期廓清的列线图模型。该模型诊断HCC的AUC在训练队列为0.934、验证队列为0.929,对≤20 mm病灶AUC分别为0.888和0.877,并提供网络和移动计算器。

要点

  • 列线图模型纳入性别、年龄、AFP、DCP、动脉期高增强和晚期廓清六个因素。
  • 训练队列诊断HCC的AUC为0.934,敏感度0.868,特异度0.895。
  • ≤20 mm病灶训练队列AUC为0.888,敏感度0.804,特异度0.870。

核心结论

  • 超声造影特征联合血清生物标志物能准确预测HCC的存在,达到最佳平衡,并提供易于使用的网络和移动计算器。

研究设计与样本

  • 回顾性研究纳入1487例接受肝脏超声造影的患者,参考标准为组织病理学或综合影像及临床随访结果。

诊断标准与关键数值

  • 训练队列列线图诊断HCC的AUC为0.934(95%CI 0.917-0.950),敏感度0.868(95%CI 0.842-0.891),特异度0.895(95%CI 0.858-0.925)。
  • 验证队列列线图诊断HCC的AUC为0.929(95%CI 0.901-0.957),敏感度0.872(95%CI 0.823-0.912),特异度0.890(95%CI 0.827-0.936)。
  • 最大直径≤20 mm病灶训练队列列线图AUC为0.888(95%CI 0.836-0.941),敏感度0.804(95%CI 0.733-0.863),特异度0.870(95%CI 0.737-0.951)。
  • 最大直径≤20 mm病灶验证队列列线图AUC为0.877(95%CI 0.789-0.965),敏感度0.768(95%CI 0.636-0.870),特异度0.885(95%CI 0.698-0.976)。
  • 最终模型包含性别、年龄、AFP、DCP、动脉期高增强和晚期廓清六个变量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the diagnostic efficacy of the contrast-enhanced ultrasound (CEUS) features combined with serum tumor biomarkers for the diagnosis of hepatocellular carcinoma (HCC).

METHODS: This retrospective study included 1487 patients who underwent liver CEUS. The reference criteria included histopathological or comprehensive imaging and the clinical follow-up results. Clinical data, serum biomarkers and CEUS features were analyzed via logistic regression analysis to determine independent factors associated with HCC and a nomogram model was built. The diagnostic performance was evaluated in terms of sensitivity, specificity, accuracy, and area under the curve (AUC), and compared with different models.

RESULTS: The final model involved sex, age, AFP, DCP, APHE, and late wash-out. The nomogram demonstrated superior diagnostic accuracy for HCC with AUC: 0.934, 95% CI: 0.917-0.950; sensitivity: 0.868, 95% CI: 0.842-0.891; specificity: 0.895, 95% CI: 0.858-0.925) in the training cohort, and with an AUC of 0.929 (95% CI: 0.901-0.957), sensitivity of 0.872 (95% CI: 0.823-0.912), and specificity of 0.890 (95% CI: 0.827-0.936) in the validation cohort. Furthermore, for lesions with a maximum diameter ≤20 mm, the nomogram maintained robust diagnostic accuracy in the training cohort (AUC 0.888, 95% CI: 0.836-0.941; sensitivity 0.804, 95% CI: 0.733-0.863; specificity 0.870, 95% CI: 0.737-0.951), and in the validation cohort (AUC: 0.877, 95% CI: 0.789-0.965; sensitivity: 0.768, 95% CI: 0.636-0.870; specificity: 0.885, 95% CI: 0.698-0.976).

CONCLUSION: CEUS features combined with the serum biomarkers accurately predicted the presence of HCC, achieving an optimal balance. With web-based and mobile calculators for easy use.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Wang F, Chen Y, Xu Y, et al. Integrating Contrast-Enhanced Ultrasound Features and Serum Biomarkers in an Online Tool Optimizes Noninvasive Hepatocellular Carcinoma Diagnosis. Ultrasound Med Biol. 2025. PMID: 41320592. doi:10.1016/j.ultrasmedbio.2025.10.239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。